The EU has awarded €9.5m to AMELIE, a ground-breaking research project into the treatment of faecal incontinence.
AMELIE aims at using cell therapy to find a possible way to cure a disease that is suffered from almost 67 million people in Europe.
The project will be co-ordinated by University College London (UCL).
As reported in AMELIE Press Release (October 2020),“The research will be conducted over five years, with separate institutions in the UK, Spain and Portugal taking the lead role at each new stage.
The project will focus on taking the patient’s own muscle cells, loading them onto specially designed microcarriers and implanting them into the damaged muscle to promote regeneration and restore normal function.”
CVBF is involved in the AMELIE project as the beneficiary in charge of CRO-like activities, providing support both to the Sponsor and to the clinical sites in the set up and conduct of the study.
The complete AMELIE Press Release is available at this link.
Further information about this project can also be found on CVBF dedicated page.